Showing results (141-150 of 690) with videos related to
Sort By:
Pageof 69
Future Oncology (London, England)|March 23, 2011
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesDavid A Reardon, Bart Neyns, Michael Weller, et al.Future Oncology (London, England)|April 26, 2018
Bevacizumab biosimilars: scientific justification for extrapolation of indicationsBarbara Melosky, David A Reardon, Andrew B Nixon, et al.Cancer|September 30, 2014
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversiesKathryn M Field, Justin T Jordan, Patrick Y Wen, et al.Plos One|February 17, 2022
Treatment standards for direct oral anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation: A survey among German stroke unitsChristian Fastner, Kristina Szabo, Melina Samartzi, et al.Current Oncology Reports|December 3, 2010
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatmentsEvanthia Galanis, Wenting Wu, Jann Sarkaria, et al.Neuroradiology|January 11, 2017
Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastomaLei Qin, Xiang Li, Amanda Stroiney, et al.Nature Reviews. Clinical Oncology|July 5, 2017
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cellsHui K Gan, Martin van den Bent, Andrew B Lassman, et al.Neuro-Oncology|November 1, 2014
Medical management of brain tumors and the sequelae of treatmentDavid Schiff, Eudocia Q Lee, Lakshmi Nayak, et al.Neuro-Oncology|May 24, 2012
Current clinical development of PI3K pathway inhibitors in glioblastomaPatrick Y Wen, Eudocia Q Lee, David A Reardon, et al.The Lancet. Oncology|February 23, 2010
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careDebashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, et al.Pageof 69